

TRANSBIG

 consortiapedia.fastercures.org/consortia/transbig/

Research Areas



Basic Research



Data-Sharing Enabler



Product Development

Data

At a Glance

- Status: **Completed Consortium**
- Year Launched: **2004**
- Initiating Organization: **Breast International Group**
- Initiator Type: **Industry**
- Location: **Europe**

Abstract

TRANSBIG comprises 28 world-class institutions in 11 countries. Each participating organization brings with it expertise that ranges from specialization in cutting-edge biomedical technologies and cancer treatment programs to representing patient groups and supporting cancer societies. Among its many strengths is the fact that TRANSBIG is linked to an already existing network of groups from around the world that conduct clinical breast cancer trials together – the Breast International Group (BIG).

Mission

The main objectives of TRANSBIG were:

to accelerate the way laboratory discoveries for breast cancer “translate” into treatments for patients (translational research)

to advance personalized treatment for breast cancer patients

to strengthen and facilitate collaboration in translational breast cancer research in Europe and internationally

Consortium History

2007 - [MindAct](#) Trial

TRANSBIG/MindAct Biobank

TRANSBIG traineeship programme

Structure & Governance

The consortium is governed by Breast International Group.

Financing

Funding from the European Commission under Framework Programme VI (FP6)

Impact/Accomplishment

Click [here](#) for a description of consortium accomplishments

Links/Social Media Feed

Homepage

<http://www.breastinternationalgroup.org/our-research/research-pro/transbig/>

Points of Contact

Breast International Group (BIG)-aisbl

Blvd de Waterloo 121

B-1000 Brussels | Belgium

VAT BE 0468 176 240

Sponsors & Partners

59 MEMBER GROUPS COVERING 55+ COUNTRIES

Updated: **06/21/2017**